Figure 3From: Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain Cost-effectiveness acceptability curve; probability that posaconazole is cost-effective relative to SAT (standard azole treatment; fluconazole or itraconazole).Back to article page